Bio Path | BPTH - Cash And Equivalent


Bio Path reported 13.65M in Cash and Equivalent for its fiscal quarter ending in September of 2022.





Cash And Equivalent Change Date
Alterity Therapeutics Limited AUD 15.77M 9.56M Jun/2023
Baxter International USD 1.97B 240M Dec/2025
Bio Path 13.65M 3.37M Sep/2022
Cipla INR 7.96B 39.9M Sep/2025
Clal Biotechnology ILS 5.73M 1.71M Dec/2023
Compugen USD 90.6M 83.14M Dec/2025
CSL USD 2.16B 633M Jun/2025
Grifols EUR 979.78M 334.84M Dec/2024
Karyopharm Therapeutics USD 60.54M 22.87M Dec/2025